AIFF · NASDAQ · Software - Application

Firefly Neuroscience (AIFF)

FDA-cleared EEG assessment systems and brain-function reports for clinicians and drug developers.

$1.14
vs last close−0.06 (−5.00%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000200000001
Cost of revenue000110000000
Gross profit0001−10000000
121133223222
Research & development000010000001
021122222222
Selling & marketing010000000000
General & administrative011122212222
Other expenses000001000000
Operating income−1−2−10−4−3−2−2−3−2−2−2
000000−1100000
Interest income000000000000
Interest expense000000000000
Other non-operating income00000−11100000
Income before tax−1−1−10−4−4−13−2−3−2−2−2
Income tax expense000000000000
Net income from continuing operations−1−1−10−4−4−13−2−3−2−2−2
Net income−1−1−10−4−4−13−2−3−2−2−2
EPS, basic−$0.08−$0.14−$0.09−$0.05−$0.61−$0.45−$1.74−$0.14−$0.20−$0.21−$0.13−$0.10
EPS, diluted−$0.08−$0.14−$0.09−$0.05−$0.61−$0.45−$1.74−$0.14−$0.20−$0.20−$0.13−$0.10
Weighted average shares, basic888878101313131621
Weighted average shares, diluted888878101313131621
EBITDA−1−1−10−4−3−13−2−2−3−2−2
Depreciation & amortization000000000000
EBIT−1−1−10−4−3−13−2−3−3−2−2